

Jose-Tomás Navarro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1965076/publications.pdf>

Version: 2024-02-01

85
papers

1,463
citations

361296

20
h-index

345118

36
g-index

98
all docs

98
docs citations

98
times ranked

1675
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. <i>Blood</i> , 2013, 122, 3251-3262.	0.6	156
2	Human immunodeficiency virus-associated plasmablastic lymphoma. <i>Cancer</i> , 2012, 118, 5270-5277.	2.0	147
3	Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 191-198.	1.7	124
4	Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. <i>British Journal of Haematology</i> , 2001, 112, 909-915.	1.2	86
5	Hepatosplenic T-Gammadelta Lymphoma in a Patient with Crohn's Disease Treated with Azathioprine. <i>Leukemia and Lymphoma</i> , 2003, 44, 531-533.	0.6	78
6	Immunohistochemical detection of MYC protein correlates with MYC gene status in aggressive B cell lymphomas. <i>Histopathology</i> , 2011, 59, 672-678.	1.6	59
7	Bortezomib plus <sc>EPOCH</sc> is effective as frontline treatment in patients with plasmablastic lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 679-682.	1.2	55
8	Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry. <i>Clinical Cancer Research</i> , 2014, 20, 1007-1019.	3.2	44
9	HIV-infection impact on clinical biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. <i>Aids</i> , 2015, 29, 811-818.	1.0	37
10	Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma. <i>Human Pathology</i> , 2004, 35, 632-635.	1.1	33
11	Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: Two cases with a different outcome. <i>American Journal of Hematology</i> , 2007, 82, 849-851.	2.0	33
12	Prognostic impact of highly active antiretroviral therapy in HIV-related Hodgkin's disease. <i>Aids</i> , 2002, 16, 1973-1976.	1.0	32
13	The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. <i>Haematologica</i> , 2005, 90, 704-6.	1.7	32
14	Epigenetic loss of m1A RNA demethylase ALKBH3 in Hodgkin lymphoma targets collagen, conferring poor clinical outcome. <i>Blood</i> , 2021, 137, 994-999.	0.6	30
15	<sc>MYC</sc> protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system. <i>Apmsis</i> , 2015, 123, 596-603.	0.9	29
16	Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART. <i>Haematologica</i> , 2008, 93, 149-150.	1.7	26
17	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , 2021, 12, 5183.	5.8	26
18	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. <i>Annals of Hematology</i> , 2014, 93, 1695-1703.	0.8	25

#	ARTICLE	IF	CITATIONS
19	Anorectal lymphoma without effusion associated with human herpesvirus-8 and type 1 epstein-barr virus in an hiv-infected patient. <i>Human Pathology</i> , 2003, 34, 630.	1.1	21
20	Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 328-332.	1.0	21
21	Primary Myeloid Sarcoma of the Gynecologic Tract: A Report of Two Cases Progressing to Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2002, 43, 2151-2153.	0.6	20
22	Favorable Impact of Virological Response to Highly Active Antiretroviral Therapy on Survival in Patients with AIDS-related Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 1837-1842.	0.6	19
23	Central nervous system involvement in <sc>AIDS</sc>-related lymphomas. <i>British Journal of Haematology</i> , 2016, 173, 857-866.	1.2	19
24	Human immunodeficiency virus-related non-Hodgkin's lymphoma. <i>Haematologica</i> , 2008, 93, 1129-1132.	1.7	18
25	Improved Outcome of AIDS-Related Lymphoma in Patients With Virologic Response to Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 347-348.	0.9	17
26	Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection. <i>Leukemia and Lymphoma</i> , 2010, 51, 2063-2069.	0.6	16
27	The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. <i>Leukemia Research</i> , 2015, 39, 853-858.	0.4	15
28	<i>In vitro</i> and <i>in vivo</i> activity of a new small-molecule inhibitor of HDAC6 in mantle cell lymphoma. <i>Haematologica</i> , 2018, 103, e537-e540.	1.7	15
29	Clinical and Therapeutic Implications of Epstein-Barr Virus in HIV-Related Lymphomas. <i>Cancers</i> , 2021, 13, 5534.	1.7	15
30	HIV-infection has no prognostic impact on advanced-stage Hodgkin lymphoma. <i>Aids</i> , 2017, 31, 1445-1449.	1.0	14
31	Acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): Clinical and biological features and comparison with other acute myeloid leukemias with cytogenetic aberrations involving long arm of chromosome 3. <i>Hematology</i> , 2015, 20, 435-441.	0.7	13
32	Hodgkin Lymphoma in People Living with HIV. <i>Cancers</i> , 2021, 13, 4366.	1.7	13
33	Long-term follow-up of patients with <sc>HIV</sc>-related diffuse large <sc>B</sc>-cell lymphomas treated in a phase <sc>II</sc> study with rituximab and <sc>CHOP</sc>. <i>British Journal of Haematology</i> , 2012, 157, 637-639.	1.2	12
34	Plasma Epstein-Barr Virus Load as an Early Biomarker and Prognostic Factor of Human Immunodeficiency Virus-related Lymphomas. <i>Clinical Infectious Diseases</i> , 2019, 68, 834-843.	2.9	11
35	Plasma Epstein-Barr viral load measurement as a diagnostic marker of lymphoma in HIV-infected patients. <i>Medicina Clínica</i> , 2010, 135, 485-490.	0.3	10
36	Cutaneous presentation of chronic lymphocytic leukemia as unique extramedullar involvement in a patient with normal peripheral blood lymphocyte count (monoclonal B-cell lymphocytosis). <i>Journal of Cutaneous Pathology</i> , 2013, 40, 740-744.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. <i>Medicina Clínica</i> , 2013, 141, 95-99.	0.3	10
38	FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 421-428.	0.7	9
39	Advanced Stage Is the Most Important Prognostic Factor for Survival in Patients with Systemic Acquired Immunodeficiency Syndrome-Related Non-Hodgkin's Lymphoma Treated with CHOP and Highly Active Antiretroviral Therapy. <i>International Journal of Hematology</i> , 2007, 86, 337-342.	0.7	8
40	Limited prognostic value of the International Prognostic Score in advanced stage human immunodeficiency virus infection-related Hodgkin lymphoma treated with the doxorubicin, bleomycin, vinblastine, and dacarbazine regimen. <i>Leukemia and Lymphoma</i> , 2009, 50, 1718-1720.	0.6	7
41	Leukoerythroblastic anemia due to oxalosis with extensive bone marrow involvement. <i>American Journal of Hematology</i> , 2008, 83, 515-516.	2.0	6
42	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1087-1091.	0.6	6
43	Flow cytometry for detection of central nervous system disease in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2190-2192.	0.6	5
44	Relapse risk after autologous stem cell transplantation in patients with lymphoma based on CD34+ cell dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 916-922.	0.6	5
45	Recomendaciones de GESIDA/PETHEMA sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. <i>Medicina Clínica</i> , 2018, 151, 39.e1-39.e17.	0.3	5
46	Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 292-295.	0.7	5
47	<i>t</i> (14;18) translocation in high grade B cell lymphoma (NOS, DH/TH) is associated with reduced progression free survival. <i>Leukemia and Lymphoma</i> , 2022, 63, 101-108.	0.6	5
48	Epstein-Barr viral loads and serum free light chains levels are potential follow-up markers of HIV-related lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 211-213.	0.6	4
49	Polycythemia Vera Evolution to Chronic Myelomonocytic Leukemia: The Prognostic Value of Next Generation Sequencing. <i>HemaSphere</i> , 2020, 4, e466.	1.2	4
50	Increased serum levels of CD44s and CD44v6 in patients with AIDS-related non-Hodgkin's lymphoma. <i>Aids</i> , 2000, 14, 1460-1461.	1.0	4
51	Flow Cytometry in the Differential Diagnosis of CD10-Positive Nodal Lymphomas. <i>Laboratory Medicine</i> , 2020, 51, 385-393.	0.8	3
52	Cytokeratin expression in plasmablastic lymphoma – a possible diagnostic pitfall in the routine workup of tumours. <i>Histopathology</i> , 2021, 78, 831-837.	1.6	3
53	Association of <i>JAK2</i> Mutation Status and Cytogenetic Abnormalities at Diagnosis in Myeloproliferative Neoplasms and Myelodysplastic/Myeloproliferative Neoplasms. <i>American Journal of Clinical Pathology</i> , 2012, 137, 677-678.	0.4	2
54	Linfomas con reordenamiento de MYC distintos del linfoma de Burkitt: comparación entre R-CHOP y la inmunoterapia tipo Burkitt. <i>Medicina Clínica</i> , 2017, 149, 339-342.	0.3	2

#	ARTICLE	IF	CITATIONS
55	Indications and use of, and incidence of major bleeding with, antithrombotic agents in myelodysplastic syndrome. <i>Leukemia Research</i> , 2018, 73, 24-28.	0.4	2
56	GESIDA/PETHEMA recommendations on the diagnosis and treatment of lymphomas in patients infected by the human immunodeficiency virus. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 39.e1-39.e17.	0.1	2
57	<scp>m7FLIPI</scp> and targeted sequencing in high-risk follicular lymphoma. <i>Hematological Oncology</i> , 2019, 37, 564-568.	0.8	2
58	Lesiones óseas en enfermedad de Erdheim-Chester. <i>Medicina Clínica</i> , 2020, 155, 233.	0.3	2
59	Prevalence, Predictive Factors Therapy and Outcome of Patients with Follicular Lymphoma Refractory to First Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 1510-1510.	0.6	2
60	Neoplasms and infections as the main causes of death in patients in complete response to HIV-related non-Hodgkin lymphoma in the combination antiretroviral therapy era: a study out of a series of 146 patients. <i>British Journal of Haematology</i> , 2013, 162, 289-291.	1.2	1
61	Pronóstico similar de los linfomas transformados y los linfomas difusos de células B grandes de novo en pacientes tratados con inmunoterapia. <i>Medicina Clínica</i> , 2017, 148, 243-249.	0.3	1
62	The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe. <i>HemaSphere</i> , 2019, 3, e291.	1.2	1
63	Reply to Lupo et al. <i>Clinical Infectious Diseases</i> , 2019, 68, 892-893.	2.9	1
64	A Pooled Analysis of 1,546 Patients with HIV-Associated Lymphoma: Assessment of Lymphoma-, HIV-, and Treatment-Specific Factors On Clinical Outcomes. <i>Blood</i> , 2012, 120, 3682-3682.	0.6	1
65	Lymphomas With MYC-Translocation Other Than Burkitt's Have An Aggressive Presentation and Poor Response To Immunochemotherapy: Study Of 34 Cases. <i>Blood</i> , 2013, 122, 5083-5083.	0.6	1
66	HIV-Associated Plasmablastic Lymphoma: A Multi-Institutional Study. <i>Blood</i> , 2011, 118, 1589-1589.	0.6	1
67	Monocyte subset distribution in myeloproliferative and myelodysplastic/myeloproliferative neoplasms with monocytosis. <i>Leukemia Research</i> , 2022, 112, 106771.	0.4	1
68	Seudoleucocitopenia EDTA-dependiente. <i>Medicina Clínica</i> , 2000, 114, 117-118.	0.3	0
69	Unique clinical implications of HIV-related lymphoma. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 171-174.	0.7	0
70	Translocation (18;22)(q21;q11.2) in B-cell lymphoproliferative disorders: a report of six cases. <i>Leukemia and Lymphoma</i> , 2015, 56, 789-792.	0.6	0
71	The influence of antiretroviral therapy on clinical aspects of HIV-related lymphoma. <i>International Journal of Hematologic Oncology</i> , 2017, 6, 35-38.	0.7	0
72	Bone lesions in Erdheim-Chester disease. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 233.	0.1	0

#	ARTICLE	IF	CITATIONS
73	Linfoma difuso de célula grande B HHV8+ en un paciente con infección por el VIH. Medicina Clínica, 2021, 157, 306-307.	0.3	0
74	Leucemia aguda mieloblástica con reordenamiento de MOZ/CBP. Medicina Clínica, 2004, 122, 639-639.	0.3	0
75	Outcome and Prognostic Factors in Patients with Hematological Malignancy That Are Admitted to the Intensive Care Unit.. Blood, 2004, 104, 5285-5285.	0.6	0
76	Comparison of Immunohistochemical (IHC) Expression Profile and Prognosis in 98 Patients with Diffuse Large B Cell Non-Hodgkin's Lymphoma (DLBCL) with and without Human Immunodeficiency Virus (HIV) Infection.. Blood, 2007, 110, 4403-4403.	0.6	0
77	Clinical and Biological Characteristics According to the Burden of JAK2V617F Mutated Allele in BCR-ABL Negative MPNs. Blood, 2012, 120, 1437-1437.	0.6	0
78	Clinical and Biological Features Of Monoclonal B-Cell Lymphocytosis In Patients Referred To Hospital. Blood, 2013, 122, 5298-5298.	0.6	0
79	Differences In Clinical-Biological Features and Outcome Between Diffuse Large B-Cell Lymphomas Of HIV-Infected and Non-HIV-Infected Patients Treated With RCHOP In The CART Era. Blood, 2013, 122, 1815-1815.	0.6	0
80	Advanced Stage Hodgkin's Lymphoma Has More Aggressive Characteristics but Similar Outcome in HIV-Infected Than in HIV-Negative Patients in the Combination Antiretroviral Therapy Era. Blood, 2014, 124, 4435-4435.	0.6	0
81	Epstein-Barr Virus Viral Loads and Serum Free Light Chains Levels Are Diagnostic Markers of Lymphoma in HIV-Infected Patients. Blood, 2014, 124, 1697-1697.	0.6	0
82	Gene Rearrangements and Other Molecular Features in Aggressive B-Cell Lymphomas of Patients with and without HIV-Infection. Blood, 2015, 126, 3874-3874.	0.6	0
83	Efficacy of a New Small-Molecule Inhibitor of Histone Deacetylase 6 (HDAC6) in Preclinical Models of B-Cell Lymphoma and Acute Myeloid Leukemia. Blood, 2018, 132, 5383-5383.	0.6	0
84	Validation of New International Prognostic Scores, Including Baseline Peripheral Blood Variables, in Patients with Diffuse Large B-Cell Lymphoma and HIV Infection Treated with R-CHOP and Combined Antiretroviral Therapy. Retrospective Study from Spanish Lymphoma Group Geltamo. Blood, 2021, 138, 2497-2497.	0.6	0
85	Abstract 4725: Efficacy of a new small-molecule inhibitor of histone deacetylase 6 (HDAC6) in preclinical models of B-cell lymphoma and acute myeloid leukemia. , 2019, , .		0